Feed / SOLV

Solventum Corporation

SOLV

Healthcare · 88.01 +2.8% today

Jodie read · what matters now

Revenue decreased 3.0% versus the comparable filing period.

The story is only the start. Jodie keeps watching the filing evidence, the companies connected to SOLV, and whether its market group begins moving.

Latest storyNo Struct brief yetJodie is monitoring new filings.
Disclosed connections19 verified links16 additional receipts in Pro
Organic co-movement groupMedical Devices & Services · ParticipantLast observed group; it is between live snapshots · See active groups →

Latest filing assessment · baseline

The latest filing shows material pressure

10-Q filed 2026-05-05 against the comparable filing from 2025-05-09.

cautious
OperationscautiousEvidence score -4
liquiditycautiousEvidence score -1
valuationdiscount

What improved

No thresholded improvement was identified.

What weakened

  • Revenue decreased 3.0% versus the comparable filing period.
  • Operating margin fell 3.3 percentage points.
  • Net income decreased 90.5% versus the comparable filing period.

Filing receipts

Investing Activities In the first three months of 2026, cash flows used in investing activities decreased compared to the first three months of 2025 primarily due to capital spending related to the Purification and Filtration business that was included in the prior year comparable period.

The decrease was primarily driven by the impact of higher product costs due to tariffs and other inflation, including freight.

MedSurg ( 61.5% of consolidated sales for the three months ended March 31, 2026) Three months ended March 31, (Millions) 2026 2025 Net sales $ 1,234 $ 1,157 Increase/(decrease) Organic growth 1.2 % 6.0 % Other 2.4 (1.0) Constant currency 3.6 5.0 Currency impact 3.0 (1.6) Reported growth 6.6 % 3.4 % Business segment operating income $ 161 $ 206 Percent change (21.8) % (6.6) % Percent of sales 13.1 % 17.8 % First quarter 2026 results: Sales in MedSurg were up 6.6%: • Organic growth was primarily driven by volume growth in I.V. site management products, including Tegaderm CHG, within our Infection Prevention and Surgical Solutions business.

Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.

Who this business touches

The relationships behind SOLV

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TMOThermo Fisher Scientific IncsupplierFull receipt with Pro →
TMOThermo Fisher Scientific IncpartnerFull receipt with Pro →

Depended on by

TMOThermo Fisher Scientific IncsupplierFull receipt with Pro →

Filing peers

Companies whose filings use similar operating language.

You can see the shape of the network here. Pro opens 16 more links, the original filing receipts, and alerts when connected names begin moving. See Pro →

What is moving around it

Live connections

SOLV is currently a Participant in the organic co-movement group Medical Devices & Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for SOLV; it is not active in the latest market snapshot.

Theme membership history

No durable theme membership has been observed for this name yet.